Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGW9QL)

Drug Name

CG-103065 Drug Info

Synonyms

Syk inhibitor (inflammation/cancer); Syk inhibitor (inflammation/cancer), CG Pharmaceuticals; Syk inhibitors (inflammation/cancer), CG Pharmaceuticals; Syk inhibitors (inflammation/cancer), CrystalGenomics

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Investigative	[1]

Cross-matching ID

PubChem CID: 6419747
ChEBI ID: CHEBI:92522
CAS Number: CAS 622387-85-3
TTD Drug ID: DMGW9QL

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tyrosine-protein kinase SYK (SYK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fostamatinib	DM6AUHV	Immune thrombocytopenic purpura	3B64.13	Approved	[2]
Fostamatinib disodium	DM3274D	Thrombocytopenia	3B64	Phase 3	[3]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[4]
TAK-659	DMJH3U0	Diffuse large B-cell lymphoma	2A81	Phase 2	[5]
GS-9876	DM9Q2B6	Cutaneous lupus erythematosus	EB5Z	Phase 2	[6]
GS-9973	DMKWCTR	Acute myeloid leukaemia	2A60	Phase 2	[7]
HM43239	DMV1SDA	Acute myeloid leukaemia	2A60	Phase 1/2	[8]
SKI-O-703	DMTSKXR	Rheumatoid arthritis	FA20	Phase 1	[6]
PRT6207	DMP5CLY	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
GSK2646264	DMQOM5V	Cutaneous lupus erythematosus	EB5Z	Phase 1	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine-protein kinase SYK (SYK)	TTOU65C	KSYK_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6046).
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Company report (Portola Pharmaceuticals)
5	J Clin Oncol 32:5s, 2014 (suppl; abstr 8580).
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43.
8	Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.
9	Advances in kinase inhibition: treating rheumatic diseases and beyond. Curr Opin Rheumatol. 2014 March; 26(2): 237-243.
10	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)